rs555347387
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 1P and 5B. PP2BP6BS2
The ENST00000257290.10(PDGFRA):c.2266G>A(p.Asp756Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000192 in 1,613,632 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D756Y) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000257290.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PDGFRA | NM_006206.6 | c.2266G>A | p.Asp756Asn | missense_variant | 16/23 | ENST00000257290.10 | NP_006197.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PDGFRA | ENST00000257290.10 | c.2266G>A | p.Asp756Asn | missense_variant | 16/23 | 1 | NM_006206.6 | ENSP00000257290 | P1 | |
PDGFRA | ENST00000507536.1 | n.692G>A | non_coding_transcript_exon_variant | 4/5 | 1 | |||||
PDGFRA | ENST00000509092.5 | n.2084G>A | non_coding_transcript_exon_variant | 15/15 | 1 | |||||
PDGFRA | ENST00000509490.5 | c.*187G>A | 3_prime_UTR_variant, NMD_transcript_variant | 17/18 | 1 | ENSP00000424218 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152170Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000478 AC: 12AN: 251072Hom.: 0 AF XY: 0.0000590 AC XY: 8AN XY: 135682
GnomAD4 exome AF: 0.0000198 AC: 29AN: 1461344Hom.: 0 Cov.: 31 AF XY: 0.0000206 AC XY: 15AN XY: 727010
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152288Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74460
ClinVar
Submissions by phenotype
Gastrointestinal stromal tumor Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 756 of the PDGFRA protein (p.Asp756Asn). This variant is present in population databases (rs555347387, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. ClinVar contains an entry for this variant (Variation ID: 348905). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PDGFRA protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 24, 2024 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 11, 2019 | The p.D756N variant (also known as c.2266G>A), located in coding exon 15 of the PDGFRA gene, results from a G to A substitution at nucleotide position 2266. The aspartic acid at codon 756 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Idiopathic hypereosinophilic syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at